About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
I
SABCS Update on HER2+ MBC: How Effective Is Margetuximab + Chemo After Prior Anti-HER2 Therapies? What Are the Available Management Options for 1L and Beyond?
By
11th Annual Midwest Regional San Antonio Breast Cancer Symposium Review
FEATURING
Ingrid Mayer
By
11th Annual Midwest Regional San Antonio Breast Cancer Symposium Review
FEATURING
Ingrid Mayer
90 views
February 23, 2021
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
London Breast Meeting
London Breast Meeting 2024
Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
07:50
Oncology Data Advisor
ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…
Feat.
K. Kalinsky
22:34
Dana-Farber Cancer Institute
What's New in Breast Cancer?
Feat.
S. Tolaney
17:35
Insights from 2023 SABCS
SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…
Feat.
P. Tarantino
30:46
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
03:24
ecancer
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…
Feat.
V. Kaklamani
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…
Feat.
S. Hurvitz
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
12:24
Stanford Medicine
HR+ mBC: CDK4/6i Progression Management
Feat.
M. Dolezal
05:45
SABCS 2022 Conference Coverage
SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…
Feat.
S. Tolaney
07:34
PrecisCa
Summary of the Updated Results of SOFT/TEXT Trials and the Meta-Anal…
Feat.
M. Pegram
11:19
Adam Brufsky
HER2+ mBC: The Role of TDM-1
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
03:36
ecancer
ESMO 2023 Insights: "Phase 3 TROPION-Breast01 Trial - Datopotam…
Feat.
A. Bardia
